KaliVir Immunotherapeutics Secures $14 Million in Latest Series A Funding Round

KaliVir Immunotherapeutics secured $14 million in its latest Series A, adding another data point to the Healthcare & Life Sciences funding market.

KaliVir Immunotherapeutics Raises $14 million in Funding

KaliVir Immunotherapeutics Raises $14M in Series A Extension Funding.

Investors Behind the Funding

The round was backed by undisclosed investors. Capvizr tracks this investor activity alongside sector momentum, co-investor patterns, and recent comparable raises.

Company Profile and Market Context

KaliVir Immunotherapeutics operates in Healthcare & Life Sciences. KaliVir Immunotherapeutics's financing adds to recent private-market activity.

Strategic Use of Funds

Advance Solid Tumor Clinical Trial | citybiz KaliVir Immunotherapeutics Closes Series A Financing KaliVir Immunotherapeutics Closes Series A Financing --Financing Enables Company t.

Looking Ahead

KaliVir Immunotherapeutics Raises $14M in Series A Extension Funding

Source reference: original announcement/article.